title: The efficacy of vortioxetine for the treatment of major depressive disorder.
abstract: Vortioxetine (Lu AA21004; Brintellix(®)) has received approval from various international regulatory agencies for the treatment of major depression. The drug molecule has a multimodal mechanism of action that projects it as a unique molecule for the treatment of major depression. These mechanisms include property to inhibit serotonin reuptake via inhibiting serotonin transporters and acting on multiple serotonin receptor subtypes. Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. The molecule has been found to be effective and well-tolerable to be administered in humans for the treatment of major depression. Precautions should be exercised when vortioxetine is prescribed with cytochrome P450 inducers and inhibitors. This review attempts to compile the efficacy profile of vortioxetine in different clinical trials and the results are compared with other standard antidepressants.
authors.affiliation: Institute of Research and Development, Gujarat Forensic Sciences University, Gandhinagar, Gujarat-382007, India.
authors.forename: Ashish
authors.initials: A
authors.lastname: Dhir
authors.forename: Jayrajsinh
authors.initials: J
authors.lastname: Sarvaiya
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D055808:Drug Discovery; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D011985:Receptors, Serotonin / Q000187:drug effects; D013440:Sulfides / Q000627:therapeutic use*; D000078784:Vortioxetine
chemical_list: D000928:Antidepressive Agents; D010879:Piperazines; D011985:Receptors, Serotonin; D013440:Sulfides; D000078784:Vortioxetine
keywords: Brintellix®; Lu AA21004; clinical studies; efficacy and safety; major depression; serotonin receptors; serotonin transporters; vortioxetine